Attorney General Jason Miyares announced that eight drug manufacturers have agreed to a nationwide settlement totaling approximately $720 million over their role in the opioid crisis. Virginia is expected to receive up to $16.4 million from these settlements.
The companies involved and their respective contributions are as follows: Mylan (now part of Viatris) will pay $284,447,916 over nine years; Hikma will contribute $95,818,293 over one to four years; Amneal will provide $71,751,010 over ten years; Apotex will pay $63,682,369 in a single year; Indivior will pay $38,022,450 over four years; Sun will contribute $30,992,087 over one to four years; Alvogen will provide $18,680,162 in a single year; and Zydus will pay $14,859,220 in a single year.
Seven of these companies are now restricted from promoting or marketing opioids and opioid products. They are also barred from producing or selling any product containing more than 40 mg of oxycodone per pill and must implement monitoring systems for suspicious orders. Indivior has agreed not to manufacture or sell opioid products for the next decade but can continue marketing medications for treating opioid use disorder.
This settlement was negotiated by Virginia alongside attorneys general from California, Colorado, Illinois, New York, North Carolina, Oregon, Tennessee, and Utah.
